Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-Bromopurine is a synthetic halogenated purine derivative and nucleoside analogue. It is primarily used as an intermediate in organic synthesis and chemical research. Studies have shown that it can inhibit tumor growth when combined with azaserine, likely by blocking guanine nucleotide biosynthesis between inosine 5'-phosphate and guanosine 5'-phosphate. This compound enhances the carcinostatic activity of azaserine in certain cancer cell models (e.g., sarcoma 180 and Ehrlich carcinoma). Additionally, its nucleosides are excellent substrates for substitution reactions with N-, O-, and S-containing nucleophiles in polar solvents. In preclinical studies, radiolabeled forms of 6-halogenopurines (including 6-bromopurine) have been explored as pro-probes for positron emission tomography to monitor multidrug resistance-associated protein function due to their ability to cross the blood-brain barrier and form glutathione conjugates exported by ATP-dependent transporters[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-bromopurine.